



OTC BB: RMCP
WWW.REVOLUTIONSMEDICAL.COM
WWW.FACEBOOK.COM/REVMED

First Quarter 2010

INVEST IN...

- 3 immediately addressable health care markets totaling more than \$14 B
- Mass market products critically needed and with universal application
- Leadership team with medical, financial and product commercialization expertise

FINANCIAL DATA

Stock Price	\$0.31
Shares Outstanding	30.4
Market Cap	\$9.4
Cash	\$0.05
Debt	\$0.5
Enterprise Value	\$9.9
Net Income ('10E)	\$0.1
Net Income ('11E)	\$9.8
Net Income ('12E)	\$25.4

VALUATION DATA

P/E ('11E)	0.03x
P/E ('12E)	0.01x
Close Comp Market Cap - AMEX: RVP	\$35.5

*All numbers in millions, except stock price and P/E ratios.
 Stock price as of February 26, 2010.
 Other information as of September 30, 2009.*

COMPANY PROFILE

Since 2005, South Carolina-based Revolutions Medical Corporation has been developing and acquiring new products and tools to make health care safer and less expensive. It is launching three business lines in the next 18 months: 1) MRI enhancement software, making image interpretation easier and more productive through color (RevColor), enhanced display (RevDisplay) and auto segmentation (Rev3D), 2) safety-engineered medical devices (SEMD) and the flagship RevVac safety syringe and 3) the Breast Biopsy System (BBS), stereotactic (minimally invasive) image-based localization technology.



MARKET OPPORTUNITY

- 1) 1 MM+ U.S. health care workers stuck with hypodermic needles annually; in some countries 90% of injections are unsafe; SEMDs now a \$3 B industry, but existing syringes are sub-optimal
- 2) Global MRI market is \$1.8 B, and exploding as the Baby Boomers age; dangerous information overload as radiologist numbers stay static; new tools are required to more efficiently/effectively interpret data
- 3) 300K annual breast cancer diagnoses in the U.S.; screening industry now a \$9.5 B market; existing non- and minimally-invasive diagnostic solutions leave much to chance; a more precise tool is critically needed

INVESTMENT PARADIGM


IDEA	INVESTMENT THESIS	CATALYSTS
<p>Never has health care been a hotter issue, and the focus of the conversation is on increased safety at dramatically reduced cost. Sound like an impossible formula? For most, yes. For Revolutions Medical it is the formula for success, and one that has them immediately positioned for a high growth future.</p>	<ul style="list-style-type: none"> • 3 recurring revenue business lines with blended gross margins projected to exceed 50% • Anticipated profitability in first full year of operations, and 320% CAGR through 2014E • 2 closest public comps have market caps of \$50 MM - \$100 MM, with syringe products inferior to RevVac. 	<p><i>Ongoing product introductions drive revenue growth.</i></p> <p><u>Q4 2009</u></p> <ol style="list-style-type: none"> 1) RevVac safety syringe mass manufacturing process began 2) MRI software suite commercial introduction: RevColor, RevDisp, Rev3D <p><u>2010 (Est. Rev: \$14.8 MM)</u></p> <ul style="list-style-type: none"> • MRI software suite commercial launch • RevVac safety syringe commercial launch • BBS - stereotactic commercial launch • 4 additional products spanning the 3 lines <p><u>2011 (Est. Rev: \$40.9 MM)</u></p> <ul style="list-style-type: none"> • 2 products rounding out BBS line

FINANCIAL SUMMARY


INCOME STATEMENT	2010E	2011E	2012E	2013E	2014E
Product Line Revenue					
<i>Syringes</i>	\$11.4	\$21.6	\$30.6	\$38.4	\$45.0
<i>MRI</i>	\$2.1	\$8.6	\$21.4	\$44.2	\$67.0
<i>BBS</i>	\$1.1	\$10.3	\$22.0	\$30.9	\$40.5
Total Revenue	\$14.8	\$40.9	\$75.1	\$115.5	\$154.5
Gross Profit	\$7.3	\$20.4	\$39.3	\$65.5	\$90.5
Gross Profit Margin	49%	50%	52%	57%	59%
Net Income	\$0.1	\$9.8	\$25.4	\$50.1	\$73.9
Net Profit Margin	0.5%	24%	34%	43%	48%
Shares Outstanding	30.4	30.4	30.4	30.4	30.4
Earnings Per Share	\$0.002	\$0.3	\$0.8	\$1.6	\$2.4

All numbers in millions, except share counts, percentages and EPS.

REVENUE GROWTH BY PRODUCT LINE



NET INCOME GROWTH



LEADERSHIP TEAM

RONDALD WHEET CEO & DIRECTOR

- 15 years of investment banking experience
- Has raised in excess of \$100 MM for small cap companies
- 6 years of small business strategic and capital markets consulting experience

THOMAS O'BRIEN PRESIDENT & DIRECTOR

- 25+ years of senior and general management experience in medical capital equipment
- Held executive positions with Pfizer, Toshiba, and Johnson & Johnson
- Was responsible for launching MRI to teaching hospitals worldwide

THOMAS BEAHM, M.D. DIRECTOR

- Certified by American Boards of Surgery and Plastic Surgery
- A member of the American Society of Plastic & Reconstructive Surgeons
- A Fellow in the American College of Surgeons

STRATEGIC PRODUCT DEVELOPMENT, INC. CONSULTANT

- 20 years of experience in developing medical and scientific products, and obtaining FDA approval
- Specialized expertise in medical imaging technology
- Strengths include national/international manufacturing management

CONTACTS

INVESTOR RELATIONS

Cirrus Financial Communications, LLC
Justin Davis
(877) 307-RMCP (7627)
Justin.Davis@CirrusFC.com
www.cirrusfc.com

COMPANY CONTACT

Revolutions Medical Corporation
Rondald Wheet
(843) 971-4848
R_Wheet@bellsouth.net
www.revolutionsmedical.com

AUDITOR

Sutton Robinson Freeman & Co., P.C.
Rick Freeman
(918) 747-7000
mail@telcpa.com
www.telcpa.com

LEGAL COUNSEL

Anslow & Jaclin, LLP
Joseph Lucosky, Esq.
(732) 409-1212
JLucosky@anslowlaw.com
www.anslowlaw.com

This document contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this document.